Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803

Purpose To determine the efficacy and safety of a biweekly regimen of leucovorin U) plus fluorouracil (FU) alone or in combination with cisplatin or irinotecan in patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase III study. Patients and Methods One hundred thirty-six patients (two were ineligible) were enrolled onto the randomized multicenter phase 11 trial. Patients received LV 200 mg/m(2) (2-hour infusion) followed by FU 400 mg/m(2) (bolus) and FU 600 mg/m(2) (22-hour continuous infusion) on days 1 and 2 every 14 days (LV5FU2, arm A), LV5FU2 plus cisplatin 50 mg/m(2) (1-hour infusion) on day 1 or 2 (arm B), or LV5FU2 plus irinotecan 180 mg/m(2) (2-hour infusion) on day 1 (arm Q. Results The overall response rates, which were confirmed by an independent expert panel, were 13% (95% Cl, 3.4% to 23.3%), 27% (95% Cl, 14.1% to 40.4%), and 40% (95% Cl, 25.7% to 54.3%) for arms A, B, and C, respectively. Median progression-free survival and overall survival times were 3.2 months (95% Cl, 1.8 to 4.6 months) and 6.8 months (95% Cl, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% Cl, 3.5 to 6.3 months) and 9.5 months (95% Cl, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% Cl, 5.5 to 8.3 months) and 11.3 months (95% Cl, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively. Conclusion Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial. (C) 2004 by American Society of Clinical Oncology